[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508638":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":33,"responsibleParty":60,"collaborators":64,"id":99,"slug":10,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":10,"enrollmentInfo":108,"targetDuration":10,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"University of Florence","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Episodic migraine",null,"Patients affected by an episodic pattern migraine(\\\u003C 15 monthly headache days) with or without aura according to ICHD-III criteria.",[13],"Drug: Rimegepant 75 MG Disintegrating Oral Tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"Chronic migraine","Patients affected by chronic migraine according to ICHD-III criteria.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Rimegepant 75 MG Disintegrating Oral Tablet","Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks",[15,9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Luigi F Iannone, MD","CONTACT","+393896969606","luigifrancesco.iannone@unifi.it",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":32},"Roberto De Icco, MD","roberto.deicco@mondino.it",[34,49],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi","RECRUITING","Florence","50134","Italy",{"type":41,"coordinates":42},"Point",[43,44],11.24626,43.77925,{"lat":44,"lon":43},[47],{"name":26,"role":27,"phone":10,"phoneExt":10,"email":48},"luigifrancesco.iannone@unimore.it",{"facility":50,"status":36,"city":51,"state":10,"zip":52,"country":39,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"IRCCS National Neurological Institute \"C. Mondino\" Foundation","Pavia","27100",{"type":41,"coordinates":54},[55,56],9.15917,45.19205,{"lat":56,"lon":55},[59],{"name":31,"role":27,"phone":10,"phoneExt":10,"email":32},{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Luigi Francesco Iannone","Researcher",[65,66,68,70,72,74,76,79,81,83,85,87,89,91,93,95,97],{"name":50,"class":6},{"name":67,"class":6},"Società Italiana per lo Studio delle Cefalee",{"name":69,"class":6},"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari",{"name":71,"class":6},"Università degli Studi dell'Aquila",{"name":73,"class":6},"University of Roma La Sapienza",{"name":75,"class":6},"Azienda Ospedaliero Universitaria Policlinico Modena",{"name":77,"class":78},"Ospedale di Piove di Sacco","UNKNOWN",{"name":80,"class":6},"Azienda Ospedaliero-Universitaria di Parma",{"name":82,"class":6},"Azienda Ospedaliera S. Maria della Misericordia",{"name":84,"class":6},"A.O.U. Città della Salute e della Scienza",{"name":86,"class":6},"Cliniche Humanitas Gavazzeni",{"name":88,"class":6},"University of Campania Luigi Vanvitelli",{"name":90,"class":6},"Ospedale Santo Stefano",{"name":92,"class":6},"Azienda Policlinico Umberto I",{"name":94,"class":6},"Auxologico San Luca",{"name":96,"class":6},"Asst Degli Spedali Civili Di Brescia",{"name":98,"class":6},"Carlo Besta Neurological Institute","100508638",false,"NCT05903027","Gepant treAtments: EffectIveNess and tolERability (GAINER)","Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)","GAINER","Inclusion Criteria:\n\n* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).\n* At least 3 MMDs\n* Good compliance to study procedures\n* Availability of headache diary at least of the preceding months before enrollment\n\nExclusion Criteria:\n\n* Subjects with contraindications for use of gepants;\n* Concomitant diagnosis of medical diseases and\u002For comorbidities that, in the Investigator's opinion might interfere with study assessments;\n* medical comorbidities that could interfere with study results;\n* Pregnancy and breastfeeding.","ALL","18 Years",{"count":109,"type":110},100,"ESTIMATED","OBSERVATIONAL","The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.",[114,115,116,117],"Migraine","Migraine With Aura","Migraine Without Aura","Chronic Migraine",[119,120,121,122,123],"Headache","Medication overuse headache","Pain","Gepant","Triptan","2026-01-19",{"date":126,"type":127},"2026-01-21","ACTUAL",{"date":129,"type":127},"2023-06-15",{"date":131,"type":110},"2026-09-15",{"name":5,"class":6},2]